Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite
暂无分享,去创建一个
L. Benet | Yong Huang | L. Frassetto | L Z Benet | Y Huang | H. Zheng | H X Zheng | L A Frassetto | Y. Huang | L. Benet | L. Frassetto | HX Zheng
[1] J. Feldman,et al. Glyburide: A Second‐generation Sulfonylurea Hypoglycemic Agent , 1985, Pharmacotherapy.
[2] J. Derancourt,et al. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. , 1989, Drug metabolism and disposition: the biological fate of chemicals.
[3] T. Self,et al. Interaction of rifampin and glyburide. , 1989, Chest.
[4] J. Kolars,et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.
[5] M. Relling,et al. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[6] Surekha,et al. Drug interaction: rifampicin and glibenclamide. , 1997, The National medical journal of India.
[7] H. Yawo,et al. Identification of a Novel Gene Family Encoding Human Liver-specific Organic Anion Transporter LST-1* , 1999, The Journal of Biological Chemistry.
[8] B. Masereel,et al. P-glycoprotein inhibition by glibenclamide and related compounds , 1999, Pflügers Archiv.
[9] H K Kroemer,et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.
[10] M. Fromm,et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. , 2000, The American journal of pathology.
[11] D. Keppler,et al. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. , 2000, American journal of physiology. Gastrointestinal and liver physiology.
[12] D. Keppler,et al. Localization and Genomic Organization of a New Hepatocellular Organic Anion Transporting Polypeptide* , 2000, The Journal of Biological Chemistry.
[13] P. Neuvonen,et al. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide , 2001, Clinical pharmacology and therapeutics.
[14] S. Vavricka,et al. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver , 2002, Hepatology.
[15] P. Neuvonen,et al. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes , 2002, Clinical pharmacology and therapeutics.
[16] Wolfgang Rohde,et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers , 2002, Clinical pharmacology and therapeutics.
[17] R. Kim,et al. Human Organic Anion Transporting Polypeptide-C (SLC21A6) Is a Major Determinant of Rifampin-Mediated Pregnane X Receptor Activation , 2003, Journal of Pharmacology and Experimental Therapeutics.
[18] Leslie Z Benet,et al. Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[19] Yuichi Sugiyama,et al. Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A , 2003, Journal of Pharmacology and Experimental Therapeutics.
[20] L. Spillane,et al. Refractory Hypoglycemia from Ciprofloxacin and Glyburide Interaction , 2004, Journal of toxicology. Clinical toxicology.
[21] Leslie Z. Benet,et al. Ex Situ Inhibition of Hepatic Uptake and Efflux Significantly Changes Metabolism: Hepatic Enzyme-Transporter Interplay , 2004, Journal of Pharmacology and Experimental Therapeutics.
[22] Leslie Z. Benet,et al. Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.
[23] Hong Sun,et al. EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN , 2004, Drug Metabolism and Disposition.
[24] L. Benet,et al. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[25] K. Brøsen,et al. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide , 2004, European Journal of Clinical Pharmacology.
[26] Y. Sawada,et al. CITRUS JUICES INHIBIT THE FUNCTION OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP-B , 2005, Drug Metabolism and Disposition.
[27] U. Christians,et al. Cyclosporine Pharmacokinetics and Dosing Modifications in Human Immunodeficiency Virus-Infected Liver and Kidney Transplant Recipients , 2005, Transplantation.
[28] O. Kohlbacher,et al. Development of a fluorescence-based assay for screening of modulators of human organic anion transporter 1B3 (OATP1B3). , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[29] L. Benet,et al. Elucidating the Effect of Final-Day Dosing of Rifampin in Induction Studies on Hepatic Drug Disposition and Metabolism , 2006, Journal of Pharmacology and Experimental Therapeutics.
[30] Leslie Z. Benet,et al. PHARMACOKINETICS OF ATORVASTATIN AND ITS HYDROXY METABOLITES IN RATS AND THE EFFECTS OF CONCOMITANT RIFAMPICIN SINGLE DOSES: RELEVANCE OF FIRST-PASS EFFECT FROM HEPATIC UPTAKE TRANSPORTERS, AND INTESTINAL AND HEPATIC METABOLISM , 2006, Drug Metabolism and Disposition.
[31] L. Benet,et al. Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.
[32] A. Treiber,et al. Inhibitory and Inductive Effects of Rifampin on the Pharmacokinetics of Bosentan in Healthy Subjects , 2007, Clinical pharmacology and therapeutics.
[33] C. Schäfer,et al. Clinical relevance. , 2010, Deutsches Arzteblatt international.